Rethinking Clinical Development with ctDNA-MRD: From Early Signals to Late-Phase Strategy

Natera is hosting an interactive working session on how ctDNA-MRD can reshape clinical development strategy and approaches, both as a biomarker to identify underserved patients that can potentially be cured with novel therapies and as a response assessment tool to accelerate both early-phase and late-phase clinical trial insights. 

Attendees will break into three focused groups based on their role and interests.